Marie Manley, partner at law firm Sidley Austin, and associates, look at how UK and EU life sciences are responding to the regulatory requirements presented by Covid-19.
Whilst the outbreak of the latest strain of Coronavirus – Covid-19 – is a scare for healthcare systems and citizens worldwide, it presents an opportunity to pharma and government to reassess the way they work together.
Professor Ian Marison (BCC) and Dr Peter Levison (Pall Corporation) speak to EPM about the most pressing challenges facing the biopharma industry and what needs to be done to tackle the growing skills shortage.
Industry trailblazers Andrea Thompson (BAE Systems), Andrea Hough (ATEC Engineering Solutions) and Donna Edwards (Made Smarter) say manufacturing SMEs can inspire a generation and close the gender gap.
Maurits Lugard, partner at Sidley Austin’s Life Sciences practice, and Anna-Shari Melin, associate at Sidley Austin write about the measures being put into place to prevent and manage medicinal product shortages in the EU.
Lu Rahman speaks to George I’ons, head of product strategy and insights at Owen Mumford Pharmaceutical Services about the near-term competitive biosimilars market in the USA and Europe, and its impact on drug delivery device design.
EPM speaks to Nigel Theobald, CEO of N4 Pharma who discusses the formulation challenges that can occur during drug development and what the company is doing to improve vaccine delivery systems.
Dr Steven Fox, CEO and chairman of biopharmaceutical company Akelos speaks to EPM about how his company wants to tackle the opioid epidemic through the development of non-addictive drugs.
